5 Oct 2020 09:00
5 October 2020
Posting of Annual Report and Accounts andupdate on arrangements for AGM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceuticals and services group, announces that its Annual Report and Accounts for the year ended 30 June 2020 is now available on the Group's website at www.clinigengroup.com and confirms the format for its Annual General Meeting ("AGM") in light of the UK Government's Covid-19 related restrictions.
Copies of the Annual Report and Accounts and Form of Proxy will be posted to shareholders later today, 5 October 2020.
Change of venue and update on arrangements
The AGM will take place at 10:00am on Thursday, 26 November 2020 at 25 Bedford Square, Bloomsbury, London WC1B 3HH, not at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ as previously advised. This is due to the restrictions imposed by the UK Government on public gatherings.
The arrangements for the AGM are as follows:
- It will not be possible for shareholders to attend the AGM in person. Please do not travel to the venue, as anyone who attempts to attend the AGM in person will be refused admission.
- The AGM will be convened with the minimum necessary quorum of two shareholders (facilitated by Clinigen) as stated in the Articles of Association. Social distancing measures will be in place.
- As shareholders will not be able to attend the AGM in person, they should vote by submitting a proxy in advance of the AGM. The Board encourages shareholders to appoint the Chairman of the meeting as their proxy with their voting instructions. Please refer to the instructions in the Form of Proxy, which has been distributed with the Annual Report and Accounts.
- The Board recommends voting in favour of all resolutions contained in the Notice of AGM as, in the Board's opinion, they are in the best interests of the Company and its shareholders as a whole.
- The AGM will focus on the formal business of the meeting as set out in the Notice of AGM. There will be no speeches at this year's AGM.
Shareholder engagement
We are disappointed that we are having to adopt these measures and appreciate our shareholders understanding in these unprecedented circumstances. We recognise the ongoing importance of communication with shareholders. Should a shareholder have a question that they would like to raise on the business of the AGM, we ask that they send it by email to matthew.parrish@clinigengroup.com by 10:00am on Tuesday, 24 November 2020. We will endeavour to respond to any questions as soon as practicable after the AGM.
Further updates
The Board will continue to monitor the situation and may, if necessary, need to make further changes to the arrangements for the AGM, including how it is conducted. Shareholders should therefore continue to monitor the Group's website and announcements.
- Ends -
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Peter Allen, Chairman Matt Parrish, Head of Investor Relations |
|
|
|
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7742 4000 |
James Mitford / Hemant Kapoor |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
|
|
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.
Clinigen now has over 1,150 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 21 of the top 25 pharmaceutical companies; interacting with over 18,000 registered users across 115 countries, shipping approximately 6.5 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com